{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:15:31Z","timestamp":1792084531174,"version":"4.4.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.mayocpiqo.2023.04.009","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T09:40:42Z","timestamp":1688118042000},"page":"276-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Contemporary Monoclonal Antibody Utilization in Glomerular Diseases"],"prefix":"10.1016","volume":"7","author":[{"given":"Iyad","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeetha","family":"Murugapandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2378-9302","authenticated-orcid":false,"given":"Bekir","family":"Tanriover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijin","family":"Thajudeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mayocpiqo.2023.04.009_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00000441-200207000-00004","article-title":"Therapeutic applications of monoclonal antibodies","volume":"324","author":"Berger","year":"2002","journal-title":"Am J Med Sci"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2023.04.009_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/14712598.2015.1045870","article-title":"Monoclonal antibodies for renal diseases: current concepts and ongoing treatments","volume":"15","author":"Santoro","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"2 Suppl 1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib4","first-page":"7","article-title":"Clinical development of Orthoclone OKT3","volume":"19","author":"Cosimi","year":"1987","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2023.04.009_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1574884712666170809124728","article-title":"Monoclonal antibodies: a review","volume":"13","author":"Singh","year":"2018","journal-title":"Curr Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.04.009_bib6","first-page":"388","article-title":"Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases","volume":"34","author":"Manrique","year":"2014","journal-title":"Nefrologia"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2023.04.009_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.006","article-title":"An overview of monoclonal antibodies","volume":"35","author":"Bayer","year":"2019","journal-title":"Semin Oncol Nurs"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development\u2014progress, remaining challenges and future innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann Med Surg (Lond)"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2023.04.009_bib9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","article-title":"Monoclonal antibody therapeutics: history and future","volume":"12","author":"Buss","year":"2012","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.xphs.2019.08.009","article-title":"Physicochemical stability of monoclonal antibodies: a review","volume":"109","author":"Le Basle","year":"2020","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.04.009_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrneph.2012.289","article-title":"Rituximab therapy in nephrotic syndrome: implications for patients' management","volume":"9","author":"Sinha","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2023.04.009_bib12","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","article-title":"Fixed dosing of monoclonal antibodies in oncology","volume":"22","author":"Hendrikx","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2023.04.009_bib14","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/archdischild-2020-321211","article-title":"Use of rituximab in paediatric nephrology","volume":"106","author":"Sinha","year":"2021","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2023.04.009_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.ackd.2021.07.006","article-title":"Immunotherapy-related acute kidney injury","volume":"28","author":"Manohar","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.mayocpiqo.2023.04.009_bib16","first-page":"61","article-title":"Glomerulonephritis in two patients with spa treated with TNF-alpha blockers and a review of the literature","volume":"15","author":"Bounia","year":"2021","journal-title":"Biologics"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2019.03.433","article-title":"Kidney Complications of immune checkpoint inhibitors: a review","volume":"74","author":"Shingarev","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2023.04.009_bib18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","article-title":"Cardiorenal complications of immune checkpoint inhibitors","volume":"14","author":"Sury","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"14","key":"10.1016\/j.mayocpiqo.2023.04.009_bib19","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.3390\/ijms21144878","article-title":"Nephrotoxicity associated with novel anticancer agents (aflibercept, dasatinib, nivolumab): case series and nephrological considerations","volume":"21","author":"Piscitani","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.mayocpiqo.2023.04.009_bib20","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.2018.7260","article-title":"Representation of patients with chronic kidney disease in trials of cancer therapy","volume":"319","author":"Kitchlu","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib21","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1016\/j.clgc.2019.04.004","article-title":"Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma and end-stage renal disease at 2 centers","volume":"17","author":"Tachibana","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2023.04.009_bib22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mds344","article-title":"Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study","volume":"24","author":"Janus","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2023.04.009_bib23","doi-asserted-by":"crossref","first-page":"e000301","DOI":"10.1136\/esmoopen-2017-000301","article-title":"Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan","volume":"3","author":"Funakoshi","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.mayocpiqo.2023.04.009_bib24","doi-asserted-by":"crossref","unstructured":"Kunizawa K, Hiramatsu R, Hoshino J, et\u00a0al. Denosumab for dialysis patients with osteoporosis: a cohort study. Sci Rep. 12 2020;10(1):2496. https:\/\/doi.org\/10.1038\/s41598-020-59143-8","DOI":"10.1038\/s41598-020-59143-8"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2023.04.009_bib25","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/ki.1986.130","article-title":"Adult-onset minimal change nephrotic syndrome: a long-term follow-up","volume":"29","author":"Nolasco","year":"1986","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.04.009_bib26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes","volume":"2","author":"Waldman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2023.04.009_bib27","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.ekir.2022.05.024","article-title":"The role of rituximab in primary focal segmental glomerular sclerosis of the adult","volume":"7","author":"Tedesco","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"48","key":"10.1016\/j.mayocpiqo.2023.04.009_bib28","doi-asserted-by":"crossref","first-page":"28799","DOI":"10.18632\/oncotarget.25612","article-title":"Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome","volume":"9","author":"Fenoglio","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.04.009_bib29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-020-01797-7","article-title":"Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis","volume":"21","author":"Hansrivijit","year":"2020","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2023.04.009_bib31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ekir.2017.03.011","article-title":"A\u00a0phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis","volume":"2","author":"Vincenti","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2023.04.009_bib34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A\u00a0proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"18","key":"10.1016\/j.mayocpiqo.2023.04.009_bib35","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1517\/14656566.8.18.3159","article-title":"Latest treatment strategies for membranous nephropathy","volume":"8","author":"Ruggenenti","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2023.04.009_bib36","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib37","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Rituximab in membranous nephropathy","volume":"6","author":"Gauckler","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib38","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib40","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fernandez-Juarez","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib41","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib42","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A\u00a0randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.40339","article-title":"Brief report: rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schonlein)","volume":"70","author":"Maritati","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2023.04.009_bib44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2023.04.009_bib46","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"9767","key":"10.1016\/j.mayocpiqo.2023.04.009_bib47","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2023.04.009_bib48","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2023.04.009_bib49","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2023.04.009_bib50","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A\u00a0secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib51","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2023.04.009_bib52","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1093\/ndt\/gfp336","article-title":"Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids","volume":"24","author":"Pepper","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2023.04.009_bib53","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2023.04.009_bib54","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1093\/ndt\/gfq256","article-title":"Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus","volume":"25","author":"Catapano","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.04.009_bib55","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2215\/CJN.04030808","article-title":"Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome","volume":"4","author":"Melander","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2023.04.009_bib56","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/0961203313483376","article-title":"Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis","volume":"22","author":"Davies","year":"2013","journal-title":"Lupus"},{"issue":"22","key":"10.1016\/j.mayocpiqo.2023.04.009_bib57","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2023.04.009_bib58","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib59","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.04.009_bib60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2023.04.009_bib61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11926-021-01010-0","article-title":"Novel therapies for ANCA-associated vasculitis","volume":"23","author":"Monti","year":"2021","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.04.009_bib62","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2023.04.009_bib63","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1074-7613(04)00112-8","article-title":"Pathogenic roles of B cells in human autoimmunity; insights from the clinic","volume":"20","author":"Martin","year":"2004","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2023.04.009_bib64","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.mayocpiqo.2023.04.009_bib65","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2023.04.009_bib66","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1681\/ASN.2019111197","article-title":"Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease","volume":"31","author":"Casal Moura","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib67","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1681\/ASN.V641178","article-title":"Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome","volume":"6","author":"Kalluri","year":"1995","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2023.04.009_bib68","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2215\/CJN.01380217","article-title":"Anti-glomerular basement membrane disease","volume":"12","author":"McAdoo","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib69","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00005792-198507000-00003","article-title":"Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors","volume":"64","author":"Johnson","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.mayocpiqo.2023.04.009_bib70","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3389\/fimmu.2019.01665","article-title":"Prognostic factors in anti-glomerular basement membrane disease: a multicenter study of 119 patients","volume":"10","author":"Marques","year":"2019","journal-title":"Front Immunol"},{"issue":"44","key":"10.1016\/j.mayocpiqo.2023.04.009_bib71","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017801","article-title":"Rituximab in treatment of anti-GBM antibody glomerulonephritis: a case report and literature review","volume":"98","author":"Uematsu-Uchida","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib72","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/0886022X.2022.2097405","article-title":"Rituximab for the treatment of refractory anti-glomerular basement membrane disease","volume":"44","author":"Yang","year":"2022","journal-title":"Ren Fail"},{"key":"10.1016\/j.mayocpiqo.2023.04.009_bib73","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2015.04.003","article-title":"Rituximab in anti-GBM disease: a retrospective study of 8 patients","volume":"60","author":"Touzot","year":"2015","journal-title":"J\u00a0Autoimmun"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2023.04.009_bib74","doi-asserted-by":"crossref","first-page":"280","DOI":"10.5414\/CN110851","article-title":"Anti-glomerular basement membrane disease: treatment outcome of cyclophosphamide vs. rituximab induction therapy regimen","volume":"98","author":"Jaryal","year":"2022","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.mayocpiqo.2023.04.009_bib75","article-title":"Anti-glomerular basement membrane diseases and thrombotic microangiopathy treated with rituximab","author":"Honda","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"issue":"15","key":"10.1016\/j.mayocpiqo.2023.04.009_bib76","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/bloodadvances.2019031914","article-title":"Pathophysiology and management of monoclonal gammopathy of renal significance","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.mayocpiqo.2023.04.009_bib78","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.2147\/IJGM.S386733","article-title":"A\u00a0Review on the diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"15","author":"Lin","year":"2022","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.mayocpiqo.2023.04.009_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1045002","article-title":"Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment","volume":"13","author":"Oganesyan","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2023.04.009_bib80","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2215\/CJN.03160316","article-title":"Bridging the divide: an onco-nephrologic approach to the monoclonal gammopathies of renal significance","volume":"11","author":"Hogan","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib81","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2215\/CJN.00560117","article-title":"Dysproteinemias and glomerular disease","volume":"13","author":"Leung","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2023.04.009_bib82","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.04.009_bib83","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ajh.24984","article-title":"Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance","volume":"93","author":"Ribes","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2023.04.009_bib84","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2023.04.009_bib85","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.ekir.2021.05.008","article-title":"Daratumumab in patients with bortezomib-refractory proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"6","author":"Almaani","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.04.009_bib86","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy\u2014understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2023.04.009_bib87","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.mayocp.2013.08.002","article-title":"Monoclonal gammopathy-associated proliferative glomerulonephritis","volume":"88","author":"Sethi","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2023.04.009_bib88","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Fontan","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2023.04.009_bib89","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000507254","article-title":"Update on C3 glomerulopathy: a complement-mediated disease","volume":"144","author":"Caravaca-Fontan","year":"2020","journal-title":"Nephron"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.04.009_bib90","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","article-title":"Eculizumab for treatment of rapidly progressive C3 glomerulopathy","volume":"65","author":"Le Quintrec","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2023.04.009_bib91","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00467-015-3061-2","article-title":"A\u00a0case of C3 glomerulonephritis successfully treated with eculizumab","volume":"30","author":"Payette","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2023.04.009_bib92","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal thrombotic microangiopathy: a review","volume":"81","author":"Genest","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"26","key":"10.1016\/j.mayocpiqo.2023.04.009_bib93","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJM200212263472616","article-title":"Thrombotic microangiopathies","volume":"347","author":"Tarr","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.mayocpiqo.2023.04.009_bib94","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2023.04.009_bib95","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/trf.17111","article-title":"Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: a single-center with homogeneous treatment experience","volume":"62","author":"Jimenez","year":"2022","journal-title":"Transfusion"},{"key":"10.1016\/j.mayocpiqo.2023.04.009_bib96","article-title":"Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","author":"Djulbegovic","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.04.009_bib97","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib98","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2023.04.009_bib99","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/ckj\/sfy035","article-title":"Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study","volume":"12","author":"Menne","year":"2019","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2023.04.009_bib100","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.04.009_bib101","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12882-020-02190-0","article-title":"Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis","volume":"22","author":"Gackler","year":"2021","journal-title":"BMC Nephrol"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454823000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454823000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:34:47Z","timestamp":1722972887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454823000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2542454823000255"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2023.04.009","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary Monoclonal Antibody Utilization in Glomerular Diseases","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2023.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}